Division of Nephrology, Department of Medicine, Section of Nephrology, Koc University School of Medicine, 34010, Istanbul, Turkey.
Cardiovascular Diseases Institute, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Int Urol Nephrol. 2023 May;55(5):1183-1191. doi: 10.1007/s11255-022-03415-x. Epub 2022 Nov 18.
Endothelial dysfunction is associated with elevated cardiovascular risk in patients with end-stage renal disease (ESRD). Kidney transplantation has demonstrated significant ability in reducing mortality and improving quality of life in recipients. Recent studies have also reported improvements in endothelial function following kidney transplantation; however, current literature is limited.
We performed a systematic review of PubMed/Medline, Web of Science, Scopus, Cochrane Library, and CINAHL databases for prospective cohort studies that assessed endothelial function prior to and following kidney transplantation via various clinical markers. Follow-up duration ranged from 1 month to 1 year. A meta-analysis of pooled data was conducted using random-effect models for four key markers: brachial artery flow-mediated dilatation (FMD), high-sensitivity C-reactive protein (hsCRP), nitroglycerin-mediated dilation (NMD), and adiponectin.
We included nine studies in our final analysis with a total of 524 patients. Significant improvement of all four biomarkers was observed after transplantation. The mean difference was 2.81% (95% CI 1.92-3.71, p < 0.00001) for FMD, 17.27 mg/L (95% CI 5.82-28.72, p = 0.003) for hsCRP, 1.05%, (95% CI 0.56-1.54, p < 0.0001) for NMD, and 9.27 µg/mL (95% CI 5.96-12.57, p < 0.00001) for adiponectin.
There is an immediate reversal of endothelial dysfunction in ESRD patients who undergo kidney transplantation, which may explain observed improvements in cardiovascular morbidity in transplant recipients. Future longitudinal studies are needed to understand possible re-emergence of endothelial dysfunction in the long-term postoperative period.
终末期肾病(ESRD)患者的内皮功能障碍与心血管风险升高有关。肾移植已证明在降低死亡率和改善受者生活质量方面具有重要作用。最近的研究还报告了肾移植后内皮功能的改善;然而,目前的文献有限。
我们对 PubMed/Medline、Web of Science、Scopus、Cochrane 图书馆和 CINAHL 数据库进行了系统回顾,以评估通过各种临床标志物在肾移植前后的内皮功能的前瞻性队列研究。随访时间从 1 个月到 1 年不等。使用随机效应模型对 4 个关键标志物(肱动脉血流介导的扩张(FMD)、高敏 C 反应蛋白(hsCRP)、硝酸甘油介导的扩张(NMD)和脂联素)进行了汇总数据的荟萃分析。
我们的最终分析纳入了 9 项研究,共 524 例患者。移植后所有四种生物标志物均显著改善。FMD 的平均差异为 2.81%(95%CI 1.92-3.71,p<0.00001),hsCRP 为 17.27mg/L(95%CI 5.82-28.72,p=0.003),NMD 为 1.05%(95%CI 0.56-1.54,p<0.0001),脂联素为 9.27µg/mL(95%CI 5.96-12.57,p<0.00001)。
接受肾移植的 ESRD 患者内皮功能障碍立即逆转,这可能解释了移植受者心血管发病率的观察到的改善。需要进一步的纵向研究来了解长期术后内皮功能障碍可能重新出现的情况。